MedTrace Logo

Study of Clinical Performance and Safety of Treatments in Degenerative Meniscopathy With Injection of Polynucleotides

NCT05322005 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-08-12

No results posted yet for this study

Summary

This is a non-randomized multicentre study for the evaluation of the clinical performance and safaty of the augmentation-to-surgery and conservative treatments for the degenerative meniscopathies, with injection of polynucleotide gel.

Conditions

  • Meniscus Tear
  • Meniscus Lesion

Interventions

PROCEDURE

partial meniscectomy

Arthroscopic procedure

DEVICE

Condrotide® (polynucleotides gel: class III medical device)

Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection

Sponsors & Collaborators

  • Mastelli S.r.l

    lead INDUSTRY

Principal Investigators

  • Elizaveta Kon, Prof. · Plastic surgery IRCCS Humanitas

  • Peter Verdonk, Prof. · Monica Ziekenhuizen Antwerpen en Deurne

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-26
Primary Completion
2024-07-27
Completion
2024-07-27

Countries

  • Belgium
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05322005 on ClinicalTrials.gov